Total Payments
$2,790
2024 Payments
$95.23
Companies
37
Transactions
118
Medicare Patients
3,354
Medicare Billing
$921,710
Payment Breakdown by Category
Food & Beverage$2,568 (92.0%)
Education$222.16 (8.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,568 | 114 | 92.0% |
| Education | $222.16 | 4 | 8.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $358.55 | 10 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $225.44 | 9 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $208.21 | 9 | $0 (2024) |
| Amgen Inc. | $205.66 | 9 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $156.66 | 8 | $0 (2024) |
| PFIZER INC. | $146.97 | 8 | $0 (2020) |
| Genentech USA, Inc. | $124.03 | 6 | $0 (2022) |
| Sirtex Medical Inc | $115.72 | 1 | $0 (2017) |
| Olympus America Inc. | $112.77 | 1 | $0 (2019) |
| Lilly USA, LLC | $106.34 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $95.23 | 4 | Novartis Pharmaceuticals Corporation ($28.25) |
| 2023 | $72.22 | 3 | Horizon Therapeutics plc ($24.44) |
| 2022 | $42.02 | 2 | Genentech USA, Inc. ($22.92) |
| 2021 | $96.63 | 5 | Cardiovascular Systems Inc. ($29.39) |
| 2020 | $760.06 | 34 | Janssen Biotech, Inc. ($146.96) |
| 2019 | $1,191 | 51 | Janssen Biotech, Inc. ($192.22) |
| 2018 | $260.32 | 13 | Novartis Pharmaceuticals Corporation ($69.41) |
| 2017 | $272.47 | 6 | Sirtex Medical Inc ($115.72) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.05 | General |
| Category: Oncology | ||||||
| 09/20/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: Oncology | ||||||
| 09/29/2023 | ImmunoGen, Inc. | Elahere (Biological) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: Oncology | ||||||
| 08/16/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: TEPEZZA | ||||||
| 05/26/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: Oncology | ||||||
| 08/30/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $22.92 | General |
| 08/26/2022 | Myriad Genetic Laboratories, Inc. | BRAC CDx (Device) | Food and Beverage | Cash or cash equivalent | $19.10 | General |
| Category: Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | ||||||
| 10/06/2021 | Cardiovascular Systems Inc. | Diamondback Peripheral (Device) | Food and Beverage | Cash or cash equivalent | $29.39 | General |
| Category: Atherectomy Device | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/28/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Oncology | ||||||
| 04/29/2021 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $12.94 | General |
| 03/04/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Oncology | ||||||
| 11/13/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $7.90 | General |
| Category: Oncology | ||||||
| 11/05/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: Oncology | ||||||
| 10/29/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Oncology | ||||||
| 10/01/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.64 | General |
| Category: Oncology | ||||||
| 09/24/2020 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Oncology | ||||||
| 09/17/2020 | EMD Serono, Inc. | Bavencio (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: Oncology | ||||||
| 08/13/2020 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $17.80 | General |
| 08/12/2020 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $28.58 | General |
| Category: Oncology | ||||||
| 07/23/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.30 | General |
| Category: Oncology | ||||||
| 07/22/2020 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Oncology | ||||||
| 07/14/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 678 | 9,214 | $732,106 | $217,640 |
| 2022 | 24 | 814 | 12,196 | $958,311 | $264,638 |
| 2021 | 26 | 925 | 32,072 | $781,897 | $220,993 |
| 2020 | 27 | 937 | 23,132 | $1.1M | $218,439 |
Total Patients
3,354
Total Services
76,614
Medicare Billing
$921,710
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 596 | $122,660 | $54,860 | 44.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 24 | 2,640 | $119,520 | $47,885 | 40.1% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 19 | 2,800 | $179,200 | $46,325 | 25.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 31 | 266 | $133,000 | $27,058 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 61 | 61 | $29,890 | $9,537 | 31.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 135 | $29,025 | $6,836 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 47 | $17,290 | $6,501 | 37.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 35 | 495 | $30,195 | $6,010 | 19.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 28 | 79 | $14,062 | $3,979 | 28.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 142 | 509 | $19,342 | $3,852 | 19.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 15 | 102 | $10,200 | $2,320 | 22.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 64 | $6,592 | $1,419 | 21.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 74 | $3,922 | $821.40 | 20.9% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 28 | 146 | $2,628 | $119.28 | 4.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 19 | 1,200 | $14,580 | $117.55 | 0.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 202 | 641 | $131,620 | $60,522 | 46.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 22 | 3,000 | $138,000 | $50,858 | 36.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2022 | 15 | 2,200 | $140,800 | $40,925 | 29.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 37 | 357 | $178,500 | $38,772 | 21.7% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2022 | 14 | 66 | $90,882 | $25,095 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $24,010 | $7,943 | 33.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 42 | 617 | $37,637 | $7,886 | 21.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 21 | 125 | $26,875 | $6,669 | 24.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 27 | 239 | $23,900 | $5,818 | 24.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 137 | 561 | $21,318 | $4,266 | 20.0% |
About Dr. Syed Ali, M.D
Dr. Syed Ali, M.D is a Hematology & Oncology healthcare provider based in Leesburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1780844233.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Syed Ali, M.D has received a total of $2,790 in payments from pharmaceutical and medical device companies, with $95.23 received in 2024. These payments were reported across 118 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($2,568).
As a Medicare-enrolled provider, Ali has provided services to 3,354 Medicare beneficiaries, totaling 76,614 services with total Medicare billing of $921,710. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Leesburg, VA
- Active Since 06/09/2008
- Last Updated 11/29/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1780844233
Products in Payments
- OPDIVO (Biological) $211.03
- IMBRUVICA (Drug) $183.99
- ERLEADA (Drug) $127.59
- SIR-Spheres Microspheres (Device) $115.72
- Olympus Biliary Devices (Device) $112.77
- Bavencio (Drug) $74.30
- TAGRISSO (Drug) $71.45
- Imbruvica (Drug) $66.88
- GAZYVA (Biological) $65.13
- VERZENIO (Drug) $63.36
- Cabometyx (Drug) $60.46
- Revlimid (Drug) $55.03
- LYNPARZA (Drug) $51.27
- Tavalisse (Drug) $50.87
- Prolia (Biological) $50.67
- GILOTRIF (Drug) $50.63
- NINLARO (Drug) $50.27
- XTANDI (Drug) $49.37
- IMFINZI (Drug) $47.43
- Erleada (Drug) $46.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Leesburg
Raj Manchandani, Md, MD
Hematology & Oncology — Payments: $19,047
Hematology & Oncology $19,047
Amitabha Sarma, M.d, M.D
Hematology & Oncology — Payments: $7,457
Hematology & Oncology $7,457
David Lee, M.d, M.D
Hematology & Oncology — Payments: $6,646
Hematology & Oncology $6,646
Shruti Tiwari, Md, MD
Hematology & Oncology — Payments: $5,424
Hematology & Oncology $5,424
Dr. Mei-Hwa Firestone, Md, MD
Hematology & Oncology — Payments: $2,482
Hematology & Oncology $2,482
Christopher Soprenuk, Md, MD
Hematology & Oncology — Payments: $1,444
Hematology & Oncology $1,444